Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 07:30 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
December 11, 2025 07:30 ET | Source: Autobahn Labs

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

Autobahn Labs and Astellas form a strategic partnership to source and develop early-stage drug discovery programs from academia.
December 09, 2025 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science

ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
December 08, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
November 20, 2025 07:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
November 06, 2025 08:00 ET | Source: BioTech Breakthrough

5th Annual BioTech Breakthrough Awards Program Honors World’s Most Innovative Life Sciences and Biotechnology Companies

LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
November 05, 2025 08:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Participate in Upcoming November Investor Conferences

Kailera will participate in several upcoming investor conferences in November: Stifel HC Conf, Jefferies London HC Conf, TD Cowen Obesity Summit
November 04, 2025 12:00 ET | Source: Kailera Therapeutics, Inc.; Hengrui Pharma

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui Pharma & Kailera Therapeutics Present Additional Data from Phase 3 Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 at Obesity Week
November 03, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Frank Clyburn to Board of Directors

Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors
October 28, 2025 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD

ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...